Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in cyclooxygenase inhibition.

Lawrence J Marnett1

  • 1Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37215, USA. marnett@toxicology.mc.vanderbilt.edu

Prostaglandins & Other Lipid Mediators
|November 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Memorial Tribute to Paul Okano (July 1, 1944-October 16, 2025).

Chemical research in toxicology·2025
Same author

A Memorial Tribute to Paul Okano (May 1, 1944-October 16, 2025).

Chemical research in toxicology·2025
Same author

Endocannabinoid oxygenation by prostaglandin H synthase-2: Chemistry and biology.

The Journal of biological chemistry·2025
Same author

Cooling-Triggered Release of Celecoxib from Implantable Alginate-Soluplus Composite Devices.

ACS biomaterials science & engineering·2025
Same author

Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer.

Molecular pharmaceutics·2025
Same author

Post-transcriptional modifications on tRNA fragments confer functional changes to high-density lipoproteins in atherosclerosis.

bioRxiv : the preprint server for biology·2025
Same journal

A comprehensive review on the mechanistics of free fatty acid-induced insulin resistance and it's therapeutics: Molecular perspectives.

Prostaglandins & other lipid mediators·2026
Same journal

NPY deficiency protects against osteoporosis by altering bone lipid metabolism.

Prostaglandins & other lipid mediators·2026
Same journal

Beyond association: Mediation roles of lipidomics and cytokine in PCOS uncovered by cross-disciplinary genomics.

Prostaglandins & other lipid mediators·2026
Same journal

Aging induces the hepatic CYP4A-20-HETE axis with stage-dependent oxylipin remodeling.

Prostaglandins & other lipid mediators·2026
Same journal

Impact of COX-2 inhibition by DuP-697 on cyclin B1/Cdc2 dynamics in human medullary thyroid carcinoma cells.

Prostaglandins & other lipid mediators·2026
Same journal

Corrigendum to "Pharmacological modulation of NF-κB-dependent COX-2/PGE₂ signaling influences inflammatory lesion development during Leishmania mexicana infection" [Prostaglandins Other Lipid Mediat. 184 (2026) 107075].

Prostaglandins & other lipid mediators·2026
See all related articles

Researchers reviewed cyclooxygenase (COX) enzyme inhibition, focusing on aspirin and COX-2 selective drugs. Dissociation rates, not association rates, determine inhibitor selectivity, guiding new drug development strategies.

Area of Science:

  • Pharmacology and Medicinal Chemistry
  • Enzyme Kinetics
  • Drug Discovery

Background:

  • Cyclooxygenase (COX) enzymes play crucial roles in inflammation and pain pathways.
  • Non-selective inhibitors like aspirin and selective COX-2 inhibitors are widely used therapeutics.
  • Understanding the precise mechanisms of enzyme inhibition is vital for developing safer and more effective drugs.

Purpose of the Study:

  • To review recent advancements in understanding the mechanism and selectivity of cyclooxygenase enzyme inhibition.
  • To analyze the structural factors influencing inhibition by aspirin and diarylheterocycle compounds.
  • To explore new strategies for developing selective COX-2 inhibitors.

Main Methods:

  • Review of existing literature on COX enzyme inhibition.

Related Experiment Videos

  • Analysis of structural determinants of inhibitor binding.
  • Kinetic investigations of inhibitor-enzyme interactions (COX-1 and COX-2).

    • Main Results:

    • The binding and inhibition kinetics of diarylheterocycles with COX-1 and COX-2 are more complex than previously thought.
    • Selectivity of inhibition is primarily governed by differences in the rates of inhibitor dissociation from the enzymes, not association rates.
    • Structural features influencing aspirin's non-selective and diarylheterocycles' COX-2 selective inhibition were examined.

    Conclusions:

    • Dissociation rates are key determinants of COX inhibitor selectivity.
    • This understanding provides a basis for designing novel COX-2 selective inhibitors with improved therapeutic profiles.
    • New strategies for developing targeted COX-2 inhibitors are emerging based on these kinetic and structural insights.